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We have constructed several hybrid human interleukin-6 (IL.6) variants in which the carboxyl-terminus, which includes a receptor binding site 
of IL-6 has been replaced with the C-terminus of various proteins homologous to human IL-6. IL-6 hybrid~ with the C-terminus ofhuman growth 
hormone and human 8ranuloeyte-colony stimulating factor maintain part of the biological activity of human IL-6. Replaein~ the C-terminus of 
human IL.6 with the C.terminus of mouse and rat IL-6 resulted in a normal or increased activity on a mouse cell line; however, this gave a low 
(to 200-fold legs) activity on a human cell line compared ~o wild-type human IL-6. We therefore conclude that the C-terminus of IL-6 plays an 
important role in the species pecificity of IL-6. 
lnterlcukin-6; Interleukin-6 receptor; Hybrid protein; Species pecificity; Growth factor 
1. INTRODUCTION 
Interleukin-6 is a cytokine with multiple functions, 
including differentiation of B-cells and T-cells, regula- 
tion of the acute phase response and differentiation of 
hemopoietic progenitor cells [1,2]. cDNAs coding for 
human, mouse and rat IL-6 have been cloned and the 
proteins have been characterized [3-5]. Amino acid 
comparison revealed an identity of the IL-6 proteins for 
mouse-human, rat-human and mouse-rat of 40%, 58% 
and 93%, respectively [4,6]. Despite this low identity, 
human IL-6 exerts activity on rat and mouse cells. How- 
ever, mouse IL-6 does not have any activity on human 
cell lines [1]. 
Although the tertiary structure of human IL-6 is un- 
known, the secondary structure predictions point to- 
wards a growth hormone-like tertiary structure [7]. This 
includes a bundle of four antiparallel a-helice,~.: with a 
distinctive loop topology. Several regions of the rodent 
and human 1L-6 proteins have a strikin$ high identity, 
especially in the middle of the protein including the four 
conserved cysteine residues and the C-terminus, indicat- 
ing that these regions are important for biological activ- 
ity [8]. Computer modelling suggests that the C-termi- 
nus of IL.6 consists of an amphipathical c~-helix, as is 
found in several homologous proteins [7]. Furthermore, 
structure-function studies have recently identified an 
IL-6 receptor binding site in the C-terminus of IL-6 [9]. 
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In this brief communication we report he construction 
and analysis of several hyrid IL-6 molecules and dem- 
onstrate that the C-terminus of IL-6 may account for 
the species pecificity of interleukin-6. 
2. MATERIALS AND METHODS 
The construction of the wild-type IL-6 geng has been described 
previously [1001 l]. The IL-6 ~ene was cloned into the expression vector 
p340. This vector is used lbr high-level xpression of an !L-6-fl-galac- 
tosidas~ fusion protein with .~mall eollagenase cleavage site as a linker 
of the two proteins. This expression vector was constructed from 
pJG200, in which the A-promotor was replaced by a P-trc promotor 
of pKK233-2 (Pharmacia LKR Biotechnology Inc., Piscataway, N J). 
A synthetic minicistron was inserted downstream of the promotor to 
increase the level of protein expression [10]. 
The hybrid IL-6 variants were constructed by replacing 19 residues 
at the C-terminus c,f IL-6 with 19 residues ofthe C-terminus ofhomol- 
ogous proteins using oligonuceotide-directed mutagenesis. The ex- 
pression vector containing the IL-6 8cue was used as a template for 
the polymerase chain reaction (PCR) using two oligonucleotides tlmt 
flanked the IL-6 gene. One oli8onuclcotide covered the N-terminal 
sequence of IL-6 and one was partly hybridized over the C-terminus 
of IL-5. The sequence of the C-terminal oligonucleotides is:(5'- 3') 
CAA GAT CTG ACA TTT GTA GTC TTC CCG GGA AGA CTA 
AGT TGT CAT GTC CTG CAG CCA CTG. The underlined part 
of the oligonucleotide is identical to the region codin 8 for Gin ~7 to 
ThP ~, The non-underlined part serves as a elonin 8site and contains 
two Bbal sites and a Bgtll site. Oligonucleotides were synthesiz~d on 
a DNA synthesizer (Applied Biosystcms 380A, Foster City, CA) and 
purified by rever.s~- phase high.performan~ liquid chromatography. 
Reagents were obtained from American Bionetics (Hayward, CA). 
PCR was performed according to standard proc.e..dur~s and a fragment 
of 560 basepairs was obtained ['12]. The PCR fragment was cloned into 
the TA  cloning TM vector pCR TM (Invitrog~n, San Di~go, CA). ARer 
cleavage with Bbsl we cloned into the lL-6 gent a 61 bp fragment, 
encoding for the C.terminus of other proteins, that was obtained by 
annealing two oligonucleotides. This resulted in the reconstruction f 
the original IL-6 gene; however, it now encodes for a human IL-6 
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variant with 19 amino acids at the C-terminus (165-183) replaced with 
the C-terminus of proteins homologous to human IL.6. All mutants 
were analyzed by dideoxy sequencing. Upon Ncol/Bglll digest of the 
TA cloning TM vector peR TM the 1L-6 hybrid gone was cloned into the 
expression vector p340. After conformation ofa correct insert using 
PCR, we used these vectors to transform Escherichia coil J M I01 cells. 
In all eases dark blue ampicillin resistant colonies were obtained and 
used for subsequent protein expression. One IL-6 variant with a dele- 
tion of amino acids 164-183 was constructed arlier [1 I]. 
Purification of our IL-6 variants was done as described previously 
[10,11]. Upon induction of protein synthesis, high amounts of the 
IL-6-~-galaetosidase fusion protein were obtained and afterwards 
partly purified, Before quantitation or use in bioassays the fusion 
protein wus ¢leawd by collagenas¢ (n.~omhinant collagenase, Bio- 
source, C:'.muriilo, CA) to release the IL-6 variant [9,10]. 
The biological activity of our IL-6 variants was te~ted on both 
mouse and human cell lines. Two bioassays were performed: a hybrid- 
oma growth factor activity assay using an IL-6 dependent mouse 
hybridoma cell line 7TDI and a hepatocyte stimulation activity assay 
using a human hepatoma cell line HEP3B2. These assays were de. 
scribed previously indetail [9,10]. The activity of the IL-6 variants was 
calculated as the mean of 2 independent preparations ofeach variant 
and expressed asa percentage ofwild-type human IL-6. 
3. RESULTS AND DISCUSSION 
In Fig. 1, the amino acid sequence of  the C-terminus 
o f lL -6  is compared with several homologous cytokines, 
such as mouse and rat IL-6 and other growth factors. 
As is indicated, several residues in this region are highly 
conserved not only between the different species but 
also between IL-6 and the evolutionary related proteins 
[7]. The C-termini o f  all o f  these proteins are predicted 
to form an amphipathical g-helix as determined by 
computer modelling [7]. For  growth hormone and IL-6 
it has been shown that this region of the proteins con- 
tains a receptor binding site [9,13]. Based on the similar- 
ity of  this region between several proteins and the 
importance of this region for biological activity, we con- 
strutted several hybrid IL-6 variants (Fig. 2). We re- 
placed the residues 165-183 of  human IL-6 with the 
corresponding C-terminal residues of  several different 
homologous proteins. The biological activity of  these 
mutants was determined on human and mouse cell lines, 
First, the importance of the C-terminus was demon- 
strated by the inactivity of  an IL-6 variant with a dele- 
tion of  the C-terminus. This mutant had no detectable 
activity (<10,000 fold less than wild-type human IL-6) 
in the human and mouse cell line assays, as was reported 
earlier [11]. Another IL-6 variant with all residues in the 
C-terminus replaced by conservative amino acid substi- 
tutions, was also inactive. Although this variant theo- 
retically has an amphipathical helical structure at the 
C-terminus, it lost all o f  its biological activity. The re- 
suits of  both these variants indicate the crucial role of  
the C-terminus for biological activity. 
In order to see whether a naturally occurring am- 
phipathieal helix is sufficient for IL-6 receptor ecogni- 
tion and for restoring biological activity, we made a 
couple o f  IL-6 hybrids with the C-terminus of human 
G-CSF and human growth hormone. The 1L-6 variant 
mo=m,u-~ t~a F z L !~ F~vz : Ia ls t  ~ co~ 
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Fig. 1. The C-terminus of interleukin-6 (IL-6) is compared with the 
C-terminus of proteins that are homologous to human IL-6. Several 
residues are conserved in IL-6 between different species, but also 
between IL-6 and other proteins uch as human growth hormone 
(hGH) and human granulocyte-colony stimulating factor (hG-CSF). 
This figure is based on the secondary structure predictions and com- 
puter ~i~odelling of these proteins by Bazan [7]. 
with the C-terminus of G-CSF had low but distinct IL-6 
activity on the mouse cell line; however, a very low 
activity on the human cell line. Although the activity on 
the mouse cell line was only 3% of  wild-type human 
IL-6, it was at least 2 orders of  magnitude more than 
the IL-6 variant with the C-terminus deleted or the I t -6  
variant with the conservative substitutions. As men- 
tioned before, IL-6 is thought o have a similar tertiary 
structure as growth hormone based on the secondary 
structure predictions. Also the receptor binding region 
o f  both proteins is thought o be in the same location. 
We constructed an IL-6 variant with the C-terminus 
replaced by the C-terminus of human growth hormone. 
Cunningham et al. showed that the affinity of growth 
hormone to its receptor could be improved four-fold by 
replacing Glu TM by Ala [13]. Therefore we constructed 
our  IL-6-growth hormone hybrid with the Glu residue 
(at position 172 in the hybrid IL-6) replaced by Ala. The 
activity o f  this mutant was low in both human and 
mouse cell lines, but as was found for the IL-6-G-CSF 
hybrid, higher than the deletion mutant. The results of 
both these hybrids indicate that a naturally o~urr ing  
amphipathical ~-helix structure at the C-terminus of  
IL-6 can maintain partly the function of  the IL-6 pro- 
tein. 
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Fig. 2. The biological activity of the various hybrid intgrleukin-6 
(1L.6) variants compared to valid-type Imnhan IL-6. The grey bar 
above the sequences indicates the amino acids that have been changed. 
The hybrid of human IL-6 with the C-terminus of' human growth 
hormone (hGH) has a substitution at1"12 (Glu to Ala) to improve its 
receptor binding, hG-CSF=human granulocytg-golony stimulating 
factor. 
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Upon replacement of the C-t~rminus of human IL-6 
with the corresponding region ot" mouse IL-6, a hybrid 
IL-6 variant was obtained that had a near normal bio- 
logical activity on a mouse cell line. Interestingly, an 
earlier attempt of Brakcnhoff to replace part of the 
C.terminus of human IL-6 by the last five correspond- 
ing residues of mouse 1L-6, resulted in an IL-6 variant 
with no detectable activity on a mouse hybridoma cell 
line [14]. This clearly indicates that the complete (19 
amino acids) helix in the C-terminus of mouse IL-6 is 
necessary for proper interaction with its own receptor. 
The activity of' this hybrid on human cells was more 
than 100-fold lower than the activity on the mouse cell 
line. This indicates that the C-terminus plays an impor- 
tant role in the species pecificity of IL-6. 
A hybrid of human IL-6 with the C.terminus of rat 
IL-6, had an activity of 12% compared to wild-type IL-6 
on the human cell line. Surprisingly the activity on the 
mouse cell line was 260% compared to wild-type human 
IL-6. The 20-fold higher activity of the human-rat IL-6 
hybrid on the mouse cell line compared to the human 
cell line also supports a role of the C-terminus in species 
specificity of IL-6. The activity of this hybrid on both 
cell lines is strikingly higlaer than the activity of the 
human-mouse hybrid. This might be explained by the 
fact that other parts of the IL-6 molecule are involved 
in receptor binding and might form a mutual binding 
site for the IL-6 receptor. The amino acid sequence 
identity between human and rat IL-6 is higher than 
human and mouse. Therefore the rat C-terminus might 
fit better with other regions of' the human IL-6 protein 
and therefore interact with a higher affinity with the 
human and mouse IL-6 receptor. This is supported by 
earlier studies of Brakenhoff et el. who suggested that 
the IL-6 receptor interaction is not confined to one part 
of the molecule, but rather mediated by different parts 
of the molecule. Based on studies using monoclonal 
antibodies, they suggested that the amino-terminal (res- 
idues 21-34) and carboxyl-terminal parts of IL-6 are in 
close proximity and both involved in receptor binding 
[15]. However, a human-mouse IL-6 hybrid in which 
the amino acids 29-34 in the N-terminus of human IL-6 
have been replaced by the sequence of mouse IL-6 dis- 
played a similar reduction of biological activity on 
human and mouse cell lines [16]. Therefore it seems that 
although this part is important for biological activity, 
it is not involved in the species pecificity of IL-6. More 
studies using hybrid IL-6 variants ubstituting different 
parts of the IL-6 protein might provide more insight in 
the species pecificity of IL-6. 
We did not perform receptor binding studies with the 
hybrid IL-6 variants. We performed a competition ex- 
periment using the human hepatoma cell line to see if 
the human-mouse IL-6 hybrid could compete with 
wild-type IL-6 for receptor binding. The activity of 
wild-type human IL-6 was not reduced by adding vari- 
ous amounts of the hybrid, and we therefore conclude 
that the loss of biological activity of this hybrid is 
caused by the inability to interact with the IL-6 receptor 
(data not shown). This is in accordance with our earlier 
studies on the C-terminus of IL-6 and the results of 
other studies, where the changes in biological activity of 
IL-6 variants were found to be closely related to its 
receptor binding ability [9,17]. 
In conclusion, we have shown that a naturally ocur- 
ring amphipathic 0:-helix of other proteins homologous 
to IL-6 at the C-terminus can maintain in part the bio- 
logical activity of IL-6. Earlier studies have already 
shown the importance of the C-terminus of IL-6 for 
biological activity and receptor binding. We suggest 
that the C-terminus of IL-6 is additionally a major de- 
terminant for the species pecificity ot" 1L-6. 
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